A non-drug treatment is currently being studied at the Toulouse University Hospital to act on the symptoms of Alzheimer’s disease. It targets inflammation in the brain and intestine using photon emissions. Over a hundred patients will be included in the study, which will also be carried out at the Lavaur, Castres and Foix hospitals.
A helmet and an abdominal belt. This is the innovative device proposed for the Light4life clinical trial, which got underway a few weeks ago at the clinical research center of the geriatrics division of Toulouse’s University Hospital Center (CHU). Launched by biotech REGEnLIFE, the trial aims to act on the symptoms of Alzheimer’s disease when it is detected at a mild to moderate stage. Light4life hopes to recruit 108 patients, aged 55 to 85, over the next 18 months, not only in Toulouse but also in the outlying hospitals of Lavaur, Castres and Foix.
